Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Clinical Trials
618
Trial Phases
5 Phases
Drug Approvals
4
Clinical Trials
Distribution across different clinical trial phases (588 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT07049575
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT07039929
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT07023627
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT07018635
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison, Madison, Wisconsin, United States
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- Drug: INCA035784
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT07008118
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 54
- Next
News
ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches
The 2025 ASCO Annual Meeting highlighted significant progress in myelofibrosis treatment, featuring novel JAK inhibitors like momelotinib and pacritinib that offer alternatives to standard ruxolitinib therapy.
Essential Thrombocythemia Market Set for Significant Growth as Novel Therapies Enter Pipeline
Essential thrombocythemia affects approximately 167,000 individuals in the US as of 2024, with 75% of cases linked to JAK2 gene mutations and only one approved therapy currently available in Europe.
Researchers Unveil New Strategies to Harness Tumor Microenvironment for Enhanced Cancer Immunotherapy
Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.
Global GVHD Clinical Trials Review Reveals Key Trends and Strategic Opportunities for 2025
A comprehensive analysis of the global Graft Versus Host Disease clinical trial landscape shows significant activity across G7 and E7 countries, offering strategic insights for pharmaceutical companies.
Promising Pipeline for Mantle Cell Lymphoma Treatment: 22+ Therapies Under Development by 20+ Companies
DelveInsight's latest report reveals a robust pipeline with 20+ companies developing 22+ therapies for mantle cell lymphoma, highlighting significant advancement in treatment options for this rare blood cancer.
Sun Pharma's Leqselvi Advances Toward Launch After Favorable US Court Ruling
Sun Pharmaceutical Industries has gained significant legal leverage after a US Court of Appeals vacated a preliminary injunction against its alopecia areata treatment Leqselvi, potentially enabling commercialization despite ongoing litigation with Incyte.
U.S. Court Ruling Clears Path for Sun Pharma's Alopecia Drug Leqselvi Launch
The U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction against Sun Pharma, allowing the company to proceed with launching Leqselvi (deuruxolitinib) for alopecia areata in the American market.
JAK Inhibitors Pipeline Expands with 55+ Drug Candidates as Major Pharma Companies Drive Innovation
The JAK inhibitors therapeutic landscape shows robust growth with over 50 pharmaceutical companies developing 55+ pipeline candidates across various clinical stages.
Tafasitamab Demonstrates Real-World Efficacy in Relapsed/Refractory DLBCL
A real-world study evaluating tafasitamab in US patients with relapsed/refractory DLBCL showed a progression-free survival of 11.3 months.
Flonoltinib and Selinexor Combinations Show Promise in Myelofibrosis Treatment
Flonoltinib demonstrated significant spleen and symptom response in myelofibrosis patients, suggesting it may be a new treatment option.